New drug duo shows promise in ovarian cancer fight
NCT ID NCT05335993
First seen Apr 05, 2026 · Last updated Jun 19, 2026 · Updated 8 times
Summary
This study tests whether adding oregovomab to the standard drug niraparib can help control recurrent ovarian cancer in 10 women whose cancer returned after initial platinum-based chemotherapy. The goal is to shrink or stabilize tumors for at least 12 to 24 weeks. This is not a cure—patients will need ongoing treatment to manage the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERITONEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke Cancer Center
Durham, North Carolina, 27710, United States
-
Stephenson Cancer Center- University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22903, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.